CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Anixa Biosciences Inc (ANIX) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Anixa Biosciences Inc (ANIX)

Pharmaceutical Preparations · market cap $92M · as of 2026-10-05

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-14
Conference
Pipeline
0
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Anixa Biosciences (ANIX) is a micro-cap pharmaceutical name with a ~$100M market capitalization and roughly $2.95/share pricing, but our structured coverage of this company is limited: we have no pipeline programs, no identified lead asset, and no upcoming catalysts in our calendar. What we do have is a financial picture showing persistent operating losses, minimal cash, and a very short reported runway, alongside modest recent insider buying.
The catalyst path
  • 2026-12-14Conferenceimp 4/10
  • 2027-01-11 (est.)Earningsimp 5/10
Pipeline

No pipeline data.

Price & technical context
3-month
-32.6%
6-month
-12.5%
12-month
-43.9%
52-wk range
$2.35–$5.22
vs 50-day MA
-14.5%
vs 200-day MA
-17.3%
Realized vol
67.5%
Max drawdown
-55.0%

Daily closes through 2026-11-20. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for ANIX (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.